Although light therapy is still considered an investigational treatment, evidence of its efficacy and safety is mounting when treating seasonal affective disorder
Seasonal affective disorder (SAD) is a pattern of major depressive episodes that occur and remit with changes in seasons. The most common type of SAD, called winter depression or winter blues, usually begins in late fall or early winter and goes away by summer. A less common type of SAD, known as summer depression, usually begins in the late spring or early summer. SAD is believed to be related to changes in the amount of daylight. Typically, the syndrome is characterized by recurrent episodes of depression, hypersomnia, increased appetite, and weight gain that begin in mid to late autumn and continue through the winter months.
There are many options for treating SAD. Although questions regarding the validity of SAD as a discrete syndrome persist and the therapeutic basis of light therapy continues to be investigated, the efficacy of light therapy is clear.
Diagnosis and Classification
SAD may occur in association with major depressive disorder (MDD), as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)1the bible of psychiatric disorders published by the American Psychiatric Association (APA). The DSM-IV describes SAD as a seasonal pattern of major depressive episodes that can occur in association with MDD. The criteria are shown in Table 1.
|Five of the following symptoms must be present during the same 2-week period; must include at least one of the first two symptoms (as indicated by self-report or observation)*.
*In patients with significant dysfunction or high level of distress in whom other factors (drugs, medical conditions, and bereavement) have been excluded.
Adapted from: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
|Table 1. Diagnostic criteria for major depression.|
Dysfunction in social or occupational settings or a high level of subjective distress distinguishes depression from temporary sadness, which is a normal part of the human experience. In persons who experience excessive sadness, levels of functioning and distress are proportional to life events. Clues to depression include a previous depressive illness or suicide attempt, family history of mood disorder, lack of social support, stressful life events, abuse of alcohol and/or other substances, and concurrent chronic medical disease, pain, and/or disability.
The DSM-IV describes SAD as a specifier, referring to the seasonal pattern of major depressive episodes that can occur within MDD (Table 2).1
Adapted from: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
|Table 2. Specific criteria for seasonal affective disorder.|
Etiology and Epidemiology
There have been numerous community-based investigations of the epidemiology of SAD.2-7 These surveys estimate that 4% to 6% of the general population experience full-blown SAD, and another 10%-20% have features consistent with a diagnosis of SAD.2,3,6,7 In children and adolescents, the incidence of SAD is much less. Based on the results of several epidemiologic studies, the prevalence rate in children is believed to be in the range of 1% to 5%.4,5
Interestingly, the prevalence of SAD in Alaska is similar to that at much lower latitudes.3 Williams and Schmidt8 reported that 20% of patients treated for recurrent depression at a northern Canadian mental health center (latitude, 54°-60°) met the operational criteria for winter depression. They also noted that this incidence rate was similar to that reported at lower latitudes. Based on these and other studies, there does not appear to be a major association between latitude (the amount of daylight each day) and the prevalence of SAD.
In community surveys, SAD is about four times more common in women than in men. The average age of onset is roughly 23 years.9 The risk of SAD appears to decrease with age.2
There is some controversy with regard to the roles of various risk factors for SAD. Blazer and colleagues2 reported that persons with SAD tend to be more educated and have greater incomes than those without the condition. The same investigators reported a greater incidence of SAD among persons who lived in rural compared to urban settings.2 These findings need to be confirmed in other surveys and in other parts of the world.
In 1984, a psychiatrist at the National Institute for Mental HealthNorman Rosenthalpublished a paper on the use of bright light therapy in patients with SAD.10 Since then, a large number of studies have confirmed the value of light therapy in SAD and have added to our understanding of the pathophysiology of the condition. It is believed that SAD is caused by a biochemical imbalance in the brain due to the shortening of daylight hours and the lack of sunlight in winter. Bright light has been shown to suppress nighttime secretion of the hormone melatonin.11 An area of the brain near the visual pathwaythe suprachiasmatic nucleusresponds to light by sending out a signal to suppress the secretion of melatonin.12
Studies in patients with SAD have focused on deviations in melatonin levels and on the pattern of melatonin secretion as possible causative factors. Persons with SAD may have impaired serotonin function in neurons leading to the suprachiasmatic nucleus, resulting in impaired melatonin secretion at night.12
Another pathogenic theory revolves around the concept of circadian rhythms (biologic variations within the 24-hour day). Investigators have shown that phase shiftingthe shifting of the internal circadian cycle to an earlier or later clock timecan be created by exposure to bright light.13 The direction and magnitude of the phase shifting depend on when the bright light occurs within the cycle. The phase-shift hypothesis of SAD postulates that the therapeutic effect of light in SAD is due to a corrective phase shifting of endogenous circadian rhythms.13 According to this hypothesis, exposure to bright light must be timed appropriately within the circadian cycle to correct a specific phase shift. For example, morning exposure to bright light should correct a phase-delayed circadian rhythm, whereas evening light exposure should worsen these rhythms. Several studies have found that patients with SAD have a phase delay in circadian rhythms that can be corrected with morning bright light treatment.14-18
The precise relationship between melatonin levels and circadian rhythms is unclear. It is believed that melatonin levels may indicate circadian phase. Several investigators have evaluated the use of melatonin in the treatment of SAD. Results have been mixed. In a study performed by Wirz-Justice and Anderson,19 neither nighttime nor morning melatonin administration had any effect on SAD symptoms. In contrast, Lewy and colleagues20 reported beneficial effects of low-dose melatonin administration timed during the afternoon to provide a circadian phase advance.
Persons who suffer from SAD do not need to wait for the spring months to overcome their feelings of depression. For mild symptoms, spending time outdoors during the day or arranging homes and workplaces to receive more sunlight may be helpful. Regular exerciseparticularly outdoor activitymay help because exercise can sometimes relieve depression. One study found that a 1-hour walk in winter sunlight was as effective as 2.5 hours under bright artificial light in relieving the symptoms of SAD.21
For more severe symptoms, light therapy (phototherapy) may help. Light therapy involves daily scheduled exposure to bright artificial light. It is believed to work by suppressing the secretion of melatonin by the brain.12 Numerous studies and meta-analyses have demonstrated the efficacy of light therapy in alleviating the symptoms of SAD.22-27 According to the Seasonal Affective Disorder Association, light therapy should be used daily in the winter months starting in early autumn when the first symptoms appear (as well as during symptomatic periods in the summer months).28
In 2001, the Health Technology and Advisory Committee (HTAC) published a report on light therapy for SAD.29 The HTAC is an independent advisory body that evaluates new and emerging health care technologies based on existing scientific research and technology assessments. According to the HTAC, light therapy is the recommended first-line treatment for SAD. The conclusions of the HTAC report are summarized in Table 3.
|1. Light therapy is an investigational treatment. Light boxes have not yet received marketing approval by the US Food and Drug Administration (FDA); however, the Agency for Health Care Policy and Research (now called the Agency for Healthcare Research and Quality [AHRQ]) published guidelines in 1993 that gave light therapy a qualified recommendation under specific conditions.
2. Both the FDA and the AHRQ state that light therapy should be administered to properly diagnosed patients (who have no psychotic disorder and who are not suicidal) under the guidance of an experienced and trained health care professional.
3. Studies available to date support reasonable beneficial effect of light therapy as a treatment of SAD in patients in whom light deprivation is thought to be the cause of illness.
|Table 3. Conclusions from the Health Technology and Advisory Committee (HTAC) Report on the Use of Light Therapy in SAD.29|
The various devices available for use in light therapy include fluorescent light boxes, a box that uses incandescent light, a portable and flexible fluorescent light lamp, an incandescent head-mounted unit (light visor or light cap), and a dawn simulator device. The fluorescent light box is the gold standard device for therapy.30 Evidence supporting the efficacy of light therapy for the treatment of SAD is substantially greater for the fluorescent light box than for the other devices.30
In general, light therapy is initiated with a 10,000-lux light box directed toward the patient at a downward slant. (Lux is the unit of measuring the illumination intensity of light.) Fluorescent light is preferred over incandescent because the small point source of the latter is more conducive to retinal damage. The patients eyes should remain open throughout the treatment session, although staring directly into the light source is not recommended. The patient should start with a single 10- to 15-minute session per day, gradually increasing the session duration to 30 to 45 minutes. Sessions should be increased to twice per day if symptoms worsen; 90 minutes a day is the conventional daily maximum duration of therapy, although there is no reason to limit the duration of sessions if side effects are not severe.31
No particular time of day appears to be optimal for light therapy. Some studies have reported the superiority of morning sessions,17 while others have shown no significant difference between times of administration32; hence, when considering what time of day to administer light therapy, consideration should be given to convenience and patient preference.
There is emerging evidence that the dose of light is important. Most controlled studies have shown that bright light is superior to dim light in the treatment of SAD.33-35 In humans, the suppression of melatonin generally requires at least 2,000 lux.12 Studies of 10,000-lux fluorescent light given for 30 minutes per day produced similar results to protocols employing 2,500 lux for 2 hours.33,36 The 10,000-lux light box has thus become the standard in clinical practice.
When properly administered, light therapy is well tolerated with few adverse events. Common side effects, which occur in about 19% of patients,29 include photophobia, headache, fatigue, and irritability. If light therapy is administered too late in the day, insomnia may be a problem.37 In persons with manic depressive disorders, skin that is sensitive to light, and/or medical conditions that make the eyes vulnerable to light damage, light therapy should be used with caution. Tanning beds should not be used to treat SAD. The light sources in tanning beds are high in ultraviolet rays, which can damage both the eyes and the skin.
The FDA considers light boxes Class III medical devicesthe most stringent regulatory category for devices; therefore, the FDA has not given final approval for manufacturers to market light boxes for the treatment of SAD. In 1993, the FDA entered into a consent decree that permits manufacturers to market their light boxes in the United States provided no significant therapeutic claims are made (light boxes are curative). According to the FDA, as long as no therapeutic claims are being made by manufacturers, light boxes are considered an alternative medicine and, therefore, are allowed to be dispensed in the United States without a prescription. Since 1997, the FDA has issued at least one warning letter to remove therapeutic claims from labeling. In 1998, the FDA convened a small, informal group to discuss a health care policy. During this meeting, it was determined that light boxes, and their relationship to SAD, did not pose a significant danger to the public. In addition, the FDA is not aware of any adverse events as a result of light box therapy.29
In general, the price of a light therapy device ranges between $200 and $500, depending on the features of the unit.38 Some insurance companies may reimburse all or a portion of the cost of a light therapy device if proper diagnosis has been made and treatment has been prescribed by a qualified health professional. Some manufacturers offer a rental program for a trial period.
Antidepressant medicationsparticularly selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, and sertralinehave been shown to relieve the symptoms of SAD.39,40 Some patients may prefer to take a pill because it is less time-consuming than sitting in front of a light box. Some individuals may need a combination of light therapy and medication in order to control symptoms. For patients with SAD and spring-summer mania, a mood stabilizer such as lithium may be useful.
The use of non-antidepressant medications for the treatment of SAD is controversial. Medications such as propranolol, L-tryptophan, hypericum, and melatonin require further study before they can be recommended for use in SAD.
Clinical-trial data evaluating the efficacy of psychotherapy specifically for SAD is lacking; however, in general, psychotherapy can be a useful adjunct for the management of depression. The efficacy of psychotherapy for depression is difficult to ascertain because of the challenges in conducting research and evaluating results. Studies usually have involved a select population of motivated individuals with the less severe forms of depression. Behavioral, cognitive, and interpersonal psychotherapies have all shown efficacy rates of 40% to 50%.41 Some comparative studies have shown that psychotherapy is more effective than antidepressant drug therapy41 except in patients with a type of depression called melancholic depression, in whom response to medication is much better. Generally, outcome is improved when antidepressant treatment and psychotherapy are combined.
Although light therapy is still considered by the FDA to be an investigational treatment, numerous well-designed clinical trials have demonstrated its efficacy and safety in patients with SAD, and it is currently recognized as a first-line treatment modality. Antidepressants with or without adjunctive psychotherapy have also been shown to be a safe and effective treatment of SAD. Further research is needed to establish the usefulness of non-antidepressant medications for the treatment of SAD.
John D. Zoidis, MD, is a contributing writer for Sleep Review.
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Blazer DG, Kessler RC, Swartz MS. Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Br J Psychiatry. 1998;172:164-167.
3. Booker JM, Hellekson CJ. Prevalence of seasonal affective disorder in Alaska. Am J Psychiatry. 1992;149:1176-1182.
4. Carskadon MA, Acebo C. Parental reports of seasonal mood and behavior changes in children. J Am Acad Child Adolesc Psychiatry. 1993;32:264-269.
5. Swedo SE, Pleeter JD, Richter DM, et al. Rates of seasonal affective disorder in children and adolescents. Am J Psychiatry. 1995;152:1016-1019.
6. Haggag A, Eklund B, Linaker O, Gotestam KG. Seasonal mood variation: an epidemiological study in northern Norway. Acta Psychiatr Scand. 1990;81:141-145.
7. Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE. Epidemiological findings of seasonal changes in mood and behavior. Arch Gen Psychiatry. 1989;46:823-33.
8. Williams RJ, Schmidt GG. Frequency of seasonal affective disorder among individuals seeking treatment at a northern Canadian mental health center. Psychiatry Res. 1993;46:41-45.
9. Oren DA, Rosenthal NE. Seasonal affective disorders. In: Paykel ES, ed. Handbook of Affective Disorders. 2nd ed. London: Churchill Livingstone; 1992:551-567.
10. Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry. 1984;41:72-80.
11. Aschoff J. Circadian timing. Ann NY Acad Sci. 1984;423:442-468.
12. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980;210:1267-1269.
13. Lewy AJ, Sack RL, Miller LS, et al. The use of plasma melatonin levels and light in the assessment and treatment of chronobiologic sleep and mood disorders. J Neural Trans. 1986;21:S311-S322.
14. Avery DH, Dahl K, Savage MV, et al. Circadian temperature and cortisol rhythms during a constant routine are phase-delayed in hypersomnic winter depression. Biol Psychiatry. 1997;41:1109-1123.
15. Dahl K, Avery DH, Lewy AJ, et al. Dim light melatonin onset and circadian temperature during a constant routine in hypersomnic winter depression. Acta Psychiatr Scand. 1993;88:60-66.
16. Endo T. Morning bright light effects on circadian rhythms and sleep structure of SAD. Jikeikai Med. 1993;40:295-307.
17. Sack RL, Lewy AJ, White DM, Singer CM, Fireman MJ, Vandiver R. Morning vs evening light treatment for winter depression: evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry. 1990;47:343-351.
18. Lewy AJ, Sack RL, Miller LS, Hoban TM. Antidepressant and circadian phase-shifting effects of light. Science. 1987;235:352-354.
19. Wirz-Justice A, Anderson J. Morning light exposure for the treatment of winter depression: the true light therapy? Psychopharmacol Bull. 1990;26:511-520.
20. Lewy AJ, Bauer VK, Cutler NL, Sack RL. Melatonin treatment of winter depression: a preliminary study. Psychiatry Res. 1998;77:57-61.
21. National Mental Health Association. Depression/Seasonal Affective Disorder. Alexandria, Va: National Mental Health Association; 2001.
22. Leppamaki SJ, Partonen TT, Hurme J, Haukka JK, Lonnqvist JK. Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry. 2002;63:316-321.
23. Koorengevel KM, Gordijn MC, Beersma DG, et al. Extraocular light therapy in winter depression: a double-blind placebo-controlled study. Biol Psychiatry. 2001;50:691-698.
24. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:883-889.
25. Terman M, Terman JS, Ross DC. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry. 1998;55:875-882.
26. Wesson VA, Levitt AJ. Light therapy for seasonal affective disorder. In: Lam RW, ed. Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Conditions. Washington, DC: American Psychiatric Press; 1998:45-90.
27. Terman M, Terman JS, Quitkin FM, McGrath PJ, Stewart JW, Rafferty B. Light therapy for seasonal affective disorder: a review of efficacy. Neuropsychopharmacology. 1989;2:1-22.
28. Treating Seasonal Affective Disorder (SAD). Steyning, England: Seasonal Affective Disorder Association; 2002.
29. Light Therapy for Seasonal Affective Disorder (SAD). St Paul, Minn: Health Technology Advisory Committee; 2001.
30. Lam RW, Tam EM, Gorman CP, et al. Light treatment. In: Lam RW, Levitt AJ, eds. Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Alberta, Canada: Clinical & Academic Publishing; 1999:64-88.
31. Rosenthal NE. Light therapy: theory and practice. Primary Psychiatry. September-October 1994:31-33.
32. Wirz-Justice A, Graw P, Krauchi K, et al. Light therapy in seasonal affective disorder is independent of time of day or circadian phase. Arch Gen Psychiatry. 1993;50:929-937.
33. Magnusson A, Kristbjarnarson H. Treatment of seasonal affective disorder with high-intensity light: a phototherapy study with an Icelandic group of patients. J Affect Disord. 1991;21:141-147.
34. Isaacs G, Stainer DS, Sensky TE, Moor S, Thompson C. Phototherapy and its mechanisms of action in seasonal affective disorder. J Affect Disord. 1988;14:13-19.
35. James SP, Wehr TA, Sack DA, et al. Treatment of seasonal affective disorder with light in the evening. Br J Psychiatry. 1985;147:424-428.
36. Terman M, Terman JS, Schlager D, et al. Efficacy of brief, intense light exposure for treatment of winter depression. Psychopharmacol Bull. 1990;26:3-11.
37. Levitt AJ, Joffe RT, Moul DE, et al. Side effects of light therapy in seasonal affective disorder. Am J Psychiatry. 1993;150:650-652.
38. Saeed SA, Bruce TJ. Seasonal affective disorders. Am Fam Physician. 1998;57:1340-1346, 1351-1352.
39. Lam RW, Gorman CP, Michalon M, et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry. 1995;152:1765-1770.
40. Moscovitch A, Blashko C, Wiseman R, Goldberg M, Martindale J. A double-blind, placebo-controlled trial of sertraline in patients with seasonal affective disorder. New Research Abstracts. Washington, DC: American Psychiatric Association; 1995.
41. Treatment of Major Depression, Clinical Practice Guideline No 5. Vol 2. Rockville, Md: Agency for Health Care Policy and Research; 1993. AHCPR Publication No. 93-0551.